Literature DB >> 36149448

Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.

Francesco Barletta1, Elio Mazzone2, Armando Stabile2, Simone Scuderi2, Giorgio Brembilla3, Mario de Angelis2, Giuseppe Ottone Cirulli2, Vito Cucchiara2, Giorgio Gandaglia2, R Jeffrey Karnes4, Morgan Roupret5, Francesco De Cobelli3, Francesco Montorsi2, Alberto Briganti2.   

Abstract

PURPOSE: We hypothesized that systematic biopsies (SBx) value for clinically significant PCa (csPCa) detection, in addition to mpMRI targeted biopsies (TBx), may vary significantly according to mpMRI index lesion (IL) characteristics.
METHODS: We identified 1350 men with an mpMRI suspicious lesion (PI-RADS ≥ 3), defined as IL, who underwent TBx and SBx at three referral centres. The outcome was SBx added value in csPCa (grade group ≥ 2 PCa detected at SBx and missed by TBx) detection. To this aim, we performed multivariable logistic regression analyses (MVA). Furthermore, we explored the interaction between IL volume and SBx csPCa added value, across different PI-RADS categories, using lowess function.
RESULTS: Overall, 569 (42%) men had csPCa at TBx and 78 (6%) csPCa were identified at SBx only. At MVA PSA (OR 0.90; p < 0.05) and IL volume (OR 0.58; p < 0.05) were associated with SBx csPCa added value. At interaction analyses, a nonlinear correlation between PI-RADS and SBx csPCa added value was identified with a decrease from roughly 10 to 4% followed by a substantial plateau at 1.2 ml and 0.6 ml for PI-RADS 3 and 4, respectively. For PI-RADS 5 lesions SBx csPCa added was constantly lower than 4%.
CONCLUSIONS: Increasing IL volume in PI-RADS 3 and 4 lesions is associated with reduction in SBx csPCa added value. For diagnostic purposes, SBx could be omitted in men with IL larger than 1.2 ml and 0.6 ml for PI-RADS 3 and 4, respectively. Conversely, for PI-RADS 5, SBx csPCa added value was minimal regardless of IL volume.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biopsy; Diagnosis; MRI; Prostate cancer; Targeted biopsy

Year:  2022        PMID: 36149448     DOI: 10.1007/s00345-022-04155-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   3.661


  17 in total

1.  Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Veeru Kasivisvanathan; Armando Stabile; Joana B Neves; Francesco Giganti; Massimo Valerio; Yaalini Shanmugabavan; Keiran D Clement; Debashis Sarkar; Yiannis Philippou; David Thurtle; Jonathan Deeks; Mark Emberton; Yemisi Takwoingi; Caroline M Moore
Journal:  Eur Urol       Date:  2019-05-24       Impact factor: 20.096

2.  Patient Experience of Systematic Versus Fusion Prostate Biopsies.

Authors:  Juho T Eineluoto; Petrus Järvinen; Tuomas Kilpeläinen; Kanerva Lahdensuo; Inari Kalalahti; Kevin Sandeman; Tuomas Mirtti; Antti Rannikko
Journal:  Eur Urol Oncol       Date:  2018-05-15

Review 3.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

4.  Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.

Authors:  Armando Stabile; Paolo Dell'Oglio; Francesco De Cobelli; Antonio Esposito; Giorgio Gandaglia; Nicola Fossati; Giorgio Brembilla; Giulia Cristel; Gianpiero Cardone; Federico Deho'; Andrea Losa; Nazareno Suardi; Franco Gaboardi; Alessandro Del Maschio; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol Oncol       Date:  2018-05-15

5.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.

Authors:  Olivier Rouvière; Philippe Puech; Raphaële Renard-Penna; Michel Claudon; Catherine Roy; Florence Mège-Lechevallier; Myriam Decaussin-Petrucci; Marine Dubreuil-Chambardel; Laurent Magaud; Laurent Remontet; Alain Ruffion; Marc Colombel; Sébastien Crouzet; Anne-Marie Schott; Laurent Lemaitre; Muriel Rabilloud; Nicolas Grenier
Journal:  Lancet Oncol       Date:  2018-11-21       Impact factor: 41.316

6.  There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.

Authors:  Paolo Dell'Oglio; Armando Stabile; Matteo Soligo; Giorgio Brembilla; Antonio Esposito; Giorgio Gandaglia; Nicola Fossati; Carlo Andrea Bravi; Federico Dehò; Francesco De Cobelli; Francesco Montorsi; R Jeffrey Karnes; Alberto Briganti
Journal:  Eur Urol Oncol       Date:  2019-03-27

7.  Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial.

Authors:  Olivier Wegelin; Leonie Exterkate; Marloes van der Leest; Johannes C Kelder; J L H Ruud Bosch; Jelle O Barentsz; Diederik M Somford; Harm H E van Melick
Journal:  Eur Urol Oncol       Date:  2019-09-11

8.  Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15.

Authors:  Alessandro Tafuri; Atsuko Iwata; Aliasger Shakir; Tsuyoshi Iwata; Chhavi Gupta; Akash Sali; Dordaneh Sugano; Abtahi Seyed Mahdi; Giovanni E Cacciamani; Masatomo Kaneko; Jie Cai; Osamu Ukimura; Vinay Duddalwar; Manju Aron; Inderbir S Gill; Suzanne L Palmer; Andre Luis Abreu
Journal:  J Urol       Date:  2021-04-05       Impact factor: 7.450

9.  Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance.

Authors:  Luke P O'Connor; Alex Z Wang; Nitin K Yerram; Lori Long; Michael Ahdoot; Amir H Lebastchi; Sandeep Gurram; Johnathan Zeng; Stephanie A Harmon; Sherif Mehralivand; Maria J Merino; Howard L Parnes; Peter L Choyke; Joanna H Shih; Bradford J Wood; Baris Turkbey; Peter A Pinto
Journal:  Eur Urol Oncol       Date:  2020-10-21

10.  MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.

Authors:  Michael Ahdoot; Andrew R Wilbur; Sarah E Reese; Amir H Lebastchi; Sherif Mehralivand; Patrick T Gomella; Jonathan Bloom; Sandeep Gurram; Minhaj Siddiqui; Paul Pinsky; Howard Parnes; W Marston Linehan; Maria Merino; Peter L Choyke; Joanna H Shih; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.